REG - Hikma Pharmaceutical - Director/PDMR Shareholding
RNS Number : 5274EHikma Pharmaceuticals Plc28 February 2020Hikma Pharmaceuticals PLC
Notification and public disclosure of transactions by persons discharging managerial responsibilities
Said Darwazah
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Said Darwazah
2
Reason for the notification
a)
Position/status
Executive Chairman
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each
ID Code: GB00B0LCW083
b)
Nature of the transaction
Release of a pledge by Darhold Limited over 1,000,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of Morgan Stanley Bank N.A. The Executive Chairman is a director of and shareholder in Darhold Limited with an equity interest of 21.99%.
c)
Price(s) and volume(s)
Price(s): £0.00p
Volume(s): 1,000,000
d)
Aggregated information
Aggregated volume: 1,000,000
Price: £0.00p
e)
Date of the transaction
28 February 2020
f)
Place of the transaction
Amman
Mazen Darwazah
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Mazen Darwazah
2
Reason for the notification
a)
Position/status
Executive Vice Chairman
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each
ID Code: GB00B0LCW083
b)
Nature of the transaction
Release of a pledge by Darhold Limited over 1,000,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of Morgan Stanley N.A. The Executive Vice Chairman is a director of and shareholder in Darhold Limited with an equity interest of 11.08%.
c)
Price(s) and volume(s)
Price(s): £0.00p
Volume(s): 1,000,000
d)
Aggregated information
Aggregated volume: 1,000,000
Price: £0.00p
e)
Date of the transaction
28 February 2020
f)
Place of the transaction
Amman
Mohammed 'Ali' Al-Husry
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Mohammed 'Ali' Al-Husry
2
Reason for the notification
a)
Position/status
Non-Executive Director
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each
ID Code: GB00B0LCW083
b)
Nature of the transaction
Release of a pledge by Darhold Limited over 1,000,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of Morgan Stanley Bank N.A. The Non-Executive Director is a director of and shareholder in Darhold Limited with an equity interest of 8.13%.
c)
Price(s) and volume(s)
Price(s): £0.00p
Volume(s): 1,000,000
d)
Aggregated information
Aggregated volume: 1,000,000
Price: £0.00p
e)
Date of the transaction
28 February 2020
f)
Place of the transaction
Amman
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDDSHBDGDDUDDDGGI
Recent news on Hikma Pharmaceuticals
See all newsREG - Hikma Pharmaceutical - Result of AGM
AnnouncementREG - Hikma Pharmaceutical - Trading Statement
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Hikma appoints new President of Generics business
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
Announcement